D2-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D2-receptor antagonist, in healthy subjects using positron emission tomography: Single dose versus steady state and dose selection

Psychopharmacology

Volumn 224, Issue 4, 2012, Pages 549-557

  Schmidt, Mark E ^a   De Boer, Peter ^a   Andrews, Randolph ^b   Neyens, Martine ^a   Rossenu, Stefaan ^a,c   William Falteos, Demiana ^a,d   Mannaert, Erik ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Abiant Inc   (United States)

^c ABLYNX NV   (Belgium)

^d AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

11C raclopride; Dopamine D2 receptor; JNJ 37822681; Positron emission tomography (PET); Schizophrenia; Single dose; Steady state

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; JNJ 37822681; RACLOPRIDE C 11; UNCLASSIFIED DRUG;

ADULT; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RECEPTOR OCCUPANCY; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDAZINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; TIME FACTORS; YOUNG ADULT;

EID: 84871614901     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2782-1     Document Type: Article

References (37)

1. Abanades S, van der Aart J, Barletta JAR, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, Zamuner S, Cunningham VJ, Rabiner EA, Laruelle MA, Gunn RN (2011) Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 31:944-952
2. Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, Strobel HW, Ravindranath V (2008) Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 3:e2337
3. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
4. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38:1614-1623
5. Collins DL, Zijdenbos AP, Kollokian V, Sled JG, Kabani NJ, Holmes CJ, Evans AC (1998) Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 17:463-468
6. Cunningham VJ, Gunn RN, Matthews JC (2004) Quantification in positron emission tomography for research in pharmacology and drug development. Nucl Med Commun 25:643-646
7. Genz A (1992) Numerical computation of multivariate normal probabilities. J Comput Graph Stat 1:141-149
8. Ghosh C, Marchi N, Desai NK, Puvenna V, Hossain M, Gonzalez-Martinez J, Alexopoulos AV, Janigro D (2011) Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia 52:562-571
9. Gibaldi M, Perrier D (1982) Equation (3.69). In: Gibaldi M, Perrier D (eds) Pharmacokinetics, 2nd edn. Marcel Dekker, New York and Basel, p 132
10. 11C]-raclopride PET study in cats. Neuropsychopharmacology 34:662-671
11. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369
12. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:L103-L107
13. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
14. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
15. 2 occupancy, clinical response, and side effects: a double blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
16. (11)C]raclopride PET study. Psychopharmacol (Berl) 217:515-523
17. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
18. 2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 342(1):91-105
19. Leysen JE, Janssen PMF, Heylen L, Van Gompet P, Lesage AS, Megens AAHP, Schotte A (1998) Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatr Clin Pract 2:S3-S17
20. 2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther 81:252-258
21. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) 110:265-272
22. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7
23. 2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875
24. 2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol 18:82-83
25. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007) "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986
26. 2 receptor antagonist, in the treatment of acute exacerbations of schizophrenia. Eur Neurophsychopharmacol (in press)
27. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38
28. 2 receptor in schizophrenia. Expert Opin Ther Targets 10:515-531
29. 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174-180
30. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
31. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321
32. 2 receptor antagonist JNJ-37822681. J Psychopharmacol (in press)
33. 11C]raclopride and positron emission tomography. J Psychopharmacol (in press)
34. Tournier N, Valette H, Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Scherrmann JM, Cisternino S, Bottlaender M (2011) Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med 52:415-423
35. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-289
36. 3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 28:608-617
37. Wu Y, Carson RE (2002) Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab 22:1440-1452